Dr. Rongfu Wang received his Ph.D. from the University of Georgia in 1992
and completed his postdoctoral fellowship at Stanford University School of
Medicine. In 1994, Dr. Wang joined Dr. Steve Rosenberg (at NCI) and was
promoted to Senior Principal Investigator. He discovered many tumor
antigens, including NY-ESO-1 and neoantigens. In 2000, Dr. Wang was
appointed Associate Professor at Baylor College of Medicine and was
promoted to full Professor in 2004. He received the Michael DeBakey
Excellence in Research Award in 2006, and the Jack L. Titus Professorship at
BCM. From 2011 to 2019, he served as the Director of the Center for
Inflammation and Epigenetics at Houston Methodist Research Institute and
Professor of Microbiology and Immunology, Weill Cornell Medicine, Cornell
University. He received numerous awards, including the President’s Award for
Transformational Excellence. Since 2019, he is Professor of Medicine,
Professor of Pediatrics, and Professor of Molecular Microbiology and
Immunology, and Endowed Chair of Cell therapy Research at
CHLA/University of Southern California. Dr. Wang has recently developed
breakthrough technologies in T cell receptor (TCR)-engineered T cell therapy
in solid cancers and therapeutic vaccines. His research interests include
cancer antigen discovery, innate immune signaling, epigenetic
reprogramming, cancer vaccine and cancer immunotherapy.
